Who Owns AtriCure Company?

AtriCure Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns AtriCure?

Understanding who owns a company like AtriCure is key to grasping its direction and influence. As a publicly traded entity, its ownership is diverse, reflecting a broad base of stakeholders. This makes knowing the key players in AtriCure company ownership a crucial piece of information for anyone interested in the medical device sector.

AtriCure, Inc., a significant player in cardiac ablation and left atrial appendage (LAA) management, transitioned to public ownership in 2005, marking a pivotal moment in its history. This move broadened its investor base considerably, moving beyond the initial founders and early venture capital support. As of July 14, 2025, with a market capitalization of $1.55 billion and employing approximately 1,300 individuals in 2024, the company's stock ownership is a dynamic landscape. Delving into AtriCure shareholders and AtriCure major investors reveals the intricate web of entities and individuals that collectively own this innovative medical device company.

The journey of AtriCure ownership began with its founding in 2000 by Michael Hooven, with its initial operations in West Chester, Ohio, before relocating its headquarters to Mason, Ohio. The company's core mission revolves around developing advanced medical devices to address atrial fibrillation (Afib) and other complex cardiac arrhythmias, with a particular focus on solutions for the left atrial appendage (LAA) and minimally invasive ablation procedures. Examining the AtriCure company ownership structure explained reveals how this vision has been supported and financed over the years, from its early stages to its current status as a publicly traded company. Understanding who owns AtriCure provides insight into its strategic decisions and its impact on the healthcare industry, especially concerning innovations like the AtriCure BCG Matrix.

For those seeking to understand AtriCure stock ownership, it's important to recognize that as a publicly traded company, its shares are held by a wide array of investors. This includes institutional investors, mutual funds, individual shareholders, and potentially company insiders. The percentage of AtriCure owned by institutional investors often indicates significant confidence from large financial entities. Furthermore, exploring AtriCure executive leadership ownership and AtriCure founder ownership percentage can offer a clearer picture of the individuals who have been instrumental in the company's growth and development. The history of AtriCure ownership also highlights shifts and changes over time, reflecting market dynamics and company performance.

AtriCure, Inc. was established in the year 2000 in West Chester, Ohio. The company's inception is credited to Michael Hooven, an individual with extensive experience, spanning over three decades, in the medical device sector. His prior roles at prominent companies like Cordis and Ethicon Endo-Surgery provided him with a deep understanding of the industry's needs. Hooven recognized a significant demand for effective surgical interventions to address atrial fibrillation, a common heart rhythm disorder.

Hooven's academic background in physics and mechanical engineering played a pivotal role in shaping the company's initial technological direction. This expertise was instrumental in the development of innovative solutions aimed at restoring normal heart rhythm. The early stages of AtriCure's journey were heavily reliant on venture capital investments. These funds were critical for supporting vital activities such as research, product development, and the initial operational setup, particularly before the company transitioned to being publicly traded.

While precise details regarding the initial equity distribution among the founding team and early angel investors are not publicly disclosed, the venture capital funding was indispensable. It provided the necessary financial resources to advance AtriCure's pioneering work, including achieving the FDA 510(k) clearance for its Isolator bipolar ablation system in 2003. Michael Hooven held significant leadership positions as Chairman and CEO of AtriCure prior to the company's public offering, underscoring his substantial influence and strategic direction during the formative years. The founding team's vision for creating advanced surgical ablation technology was directly translated into the strategic deployment of this early capital and the company's initial product development efforts.

Founding Year

AtriCure was founded in 2000.

Founder

Michael Hooven is the founder of AtriCure.

Founder's Expertise

Hooven possesses over 30 years of experience in the medical device field.

Initial Focus

The company's early focus was on developing technologies for atrial fibrillation.

Early Funding

Venture capital was the primary source of early financial backing.

Key Early Product Approval

The Isolator bipolar ablation system received FDA 510(k) clearance in 2003.

Founders and Early Ownership Dynamics

The initial ownership structure of AtriCure was heavily influenced by its founder, Michael Hooven, and the venture capital firms that provided crucial early-stage funding. Hooven's leadership as Chairman and CEO before the company's public offering indicates a significant stake and control in the nascent enterprise. The venture capital investments were essential for driving innovation and bringing the company's core technologies to market, thereby shaping the early AtriCure company ownership structure. Understanding the Revenue Streams & Business Model of AtriCure provides context for how this early ownership translated into business strategy and growth.

• Michael Hooven, with a background in physics and mechanical engineering, founded AtriCure in 2000.
• Early funding was primarily sourced from venture capital, essential for research and development.
• The company's initial focus was on surgical solutions for atrial fibrillation.
• Michael Hooven served as Chairman and CEO before the company's public offering.
• The Isolator bipolar ablation system received FDA 510(k) clearance in 2003, a key milestone.

AtriCure SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership journey of AtriCure began with its Initial Public Offering (IPO) on August 5, 2005, when it started trading on NASDAQ under the symbol 'ATRC'. This event was pivotal, raising approximately $38.5 million and significantly boosting the company's capital for growth, research, and development. The market capitalization has seen substantial growth, increasing from $167.60 million in August 2005 to an estimated $1.52 billion as of July 15, 2025, marking an impressive 806.51% rise. This transformation from a privately held, venture-backed entity to a publicly traded company has been instrumental in facilitating strategic moves, such as the acquisitions of nContact in 2015 and SentreHEART in 2019, which broadened its product offerings and market presence.

As a publicly traded company, AtriCure's ownership is now spread across a wide array of shareholders. These include significant holdings by institutional investors, mutual funds, index funds, and company insiders. As of July 3, 2025, there are 476 institutional owners holding a total of 66,255,592 shares. In April 2025, institutional investors collectively owned 106.29% of the company's shares, with mutual funds showing a slight increase in their stake, moving from 76.54% to 76.85% during the same period. Key institutional shareholders include Vanguard Group Inc, BlackRock, Inc., Alliancebernstein L.p., Hood River Capital Management LLC, and Macquarie Group Ltd. Insider ownership accounted for 3.49% as of April 2025. Michael H. Carrel, the current President and CEO, holds a direct stake of 1.76% as of March 9, 2025. Understanding who owns AtriCure provides insight into the company's strategic direction and stability.

The evolution of AtriCure's ownership structure, from its early private stages to its current public status, has been a defining factor in its growth trajectory. The substantial capital raised through its IPO and subsequent equity offerings has fueled innovation and strategic acquisitions, allowing the company to compete effectively within the medical device sector, a market with a dynamic Competitors Landscape of AtriCure.

Key Ownership Insights

AtriCure's ownership is predominantly held by institutional investors, reflecting confidence in its market position and future prospects.

• 476 institutional owners as of July 3, 2025.
• Institutional investors held 106.29% of shares in April 2025.
• Mutual funds increased their holdings to 76.85% in April 2025.
• Insider ownership stood at 3.49% as of April 2025.

AtriCure PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

AtriCure's Board of Directors is tasked with overseeing the company's operations, focusing on transparency, accountability, and security. As of July 2025, the board includes Michael H. Carrel, President and Chief Executive Officer, and Robert S. White, Chair of the Board. Other members are Regina E. Groves, B. Kristine Johnson, Shlomi Nachman, Karen N. Prange, Deborah H. Telman, Sven A. Wehrwein, and Maggie S. Yuen. Shlomi Nachman joined the board in January 2024, bringing extensive experience from the medical device sector.

The voting power for AtriCure common stock operates on a one-share-one-vote basis. Stockholders who held common stock by the close of business on March 27, 2025, were eligible to vote at the Annual Meeting on May 19, 2025. The company's 2025 proxy statement detailed proposals for the election of nine directors, ratification of the independent registered public accounting firm, and advisory votes on executive compensation. While there are no indications of dual-class shares or special voting rights, CEO Michael Carrel directly owns 1.45% of the company's shares, valued at approximately $21.84 million. The board recommended voting 'For' all proposals, including the Say-on-Pay proposal, as noted in the proxy statement filed on April 7, 2025, despite differing recommendations from Institutional Shareholder Services ('ISS') and Glass Lewis. The average tenure of the board members is 8.3 years, indicating a seasoned leadership team.

The voting structure for AtriCure common stock is straightforward, with each share granting one vote. This ensures that AtriCure shareholders have a direct say in company matters, from electing directors to approving executive compensation. Understanding this structure is key to grasping AtriCure company ownership and how decisions are made. For those interested in the company's journey, a Brief History of AtriCure offers valuable context.

Understanding AtriCure Stock Ownership

AtriCure's ownership is primarily determined by its shareholders, with a one-share-one-vote system in place. This means that the influence of AtriCure shareholders is directly proportional to the number of shares they hold.

• The CEO, Michael Carrel, holds a significant stake of 1.45%.
• Institutional investors often play a major role in publicly traded companies like AtriCure.
• The board's recommendations are crucial for shareholder voting outcomes.
• Understanding AtriCure company ownership structure helps in analyzing its strategic direction.

AtriCure Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, AtriCure has experienced significant financial growth, influencing its ownership trends. For the full year 2024, the company reported total revenue of $465.3 million, representing a 16.5% increase compared to 2023. This upward trajectory is projected to continue into 2025, with an anticipated revenue range of $517 million to $527 million and an adjusted EBITDA between $40 million and $44 million. This sustained performance is a key factor for investors considering AtriCure ownership.

The company's strategic focus has been on product innovation and expanding manufacturing capabilities, rather than major acquisitions since 2019. Leadership, including CEO Michael Carrel, remains instrumental in guiding the company's direction, with executive compensation linked to performance. As of July 3, 2025, institutional investors are the dominant force in AtriCure company ownership, with 476 such entities holding a substantial portion of the company's shares. Insider ownership, at 4.28% as of April 2025, shows relative stability, underscoring the significant influence of institutional stakeholders on AtriCure's long-term strategy and stability. Understanding these dynamics is crucial for anyone looking into who owns AtriCure.

The consistent growth and strategic investments in research and development, clinical science, and physician education are key drivers influencing AtriCure stock ownership. These factors contribute to the company's appeal among institutional investors, who play a significant role in shaping its future. For those interested in the AtriCure company ownership structure, these financial and strategic developments are paramount.

Institutional Investor Dominance

As of July 3, 2025, a significant number of institutional investors, totaling 476, hold substantial stakes in the company. This indicates a strong reliance on large financial entities for AtriCure company ownership. Their investment decisions often reflect confidence in the company's long-term growth prospects.

Stable Insider Holdings

Insider ownership, reported at 4.28% in April 2025, demonstrates a stable commitment from company executives and directors. This level of ownership can signal alignment between leadership and shareholder interests, providing a degree of confidence for other AtriCure shareholders.

Revenue Growth and Market Position

The company's robust revenue growth, with a 16.5% increase in 2024 and a projected 13.6% rise in Q1 2025, is a primary attraction for investors. This financial performance is a key indicator for those researching who owns AtriCure and why.

Strategic Focus on Innovation

AtriCure's strategic emphasis on product innovation and expanding manufacturing capabilities, rather than acquisitions, shapes its ownership landscape. This focus on organic growth is a critical aspect of its Marketing Strategy of AtriCure and influences investor sentiment.

AtriCure Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔